Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - PubMed
4 hours ago
- #Obesity Treatment
- #Phase 3 Trial
- #Survodutide
- Survodutide, a glucagon/GLP-1 receptor dual agonist, was evaluated in a phase 3 trial for adults with obesity and at-risk MASLD.
- The trial involved 216 participants randomized to survodutide or placebo, meeting co-primary endpoints of ≥30% liver fat reduction and significant body weight loss at 48 weeks.
- Adverse events were primarily gastrointestinal, mild-to-moderate, and often linked to dose escalation, with limitations including short duration and limited geographic recruitment.